KF
CADL icon

Krilogy Financial’s Candel Therapeutics CADL Stock Holding History

Krilogy Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155K Buy
30,065
+6,065
+25% +$33K 0.01% 917
2025
Q4 		$144K Buy
+24,000
New +$129K ﹤0.01% 895

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Krilogy Financial's CADL Position: Q1 2026 in Review

Krilogy Financial increased its Candel Therapeutics (CADL) stake by 25% in Q1 2026, buying an estimated $33K and bringing the position to 30,065 shares worth $155K. The position accounts for 0.01% of the portfolio, ranked #917.

Krilogy Financial first reported a position in CADL in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Krilogy Financial held 30,065 shares of Candel Therapeutics worth $155K as of Q1 2026.
  • Krilogy Financial bought 6,065 Candel Therapeutics shares in Q1 2026, an estimated $33K.
  • Candel Therapeutics made up 0.01% of Krilogy Financial's portfolio in Q1 2026, its #917 holding.
  • Krilogy Financial first reported a position in Candel Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Krilogy Financial's 13F filing for Q1 2026, filed 17 Apr 2026.